TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01525979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-related unilateral arm training
Description: The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-related unilateral arm training
Description: The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-related bilateral arm training
Description: This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-related bilateral arm training
Description: This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted bilateral arm training
Description: The Bi-Manu-Track used in this project (Reha-Stim Co., Berlin, Germany) enables the symmetric practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension. Each movement has 3 computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed, range of motion, and resistance individually adjustable; (2) active-passive, with the unaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted unilateral arm training
Description: The robot-assisted unilateral arm training group will use mode 1 and 3: (1) passive, affected arm being moved by the machine with speed and range of motion individually adjustable; and (2) active, with the affected arm actively moving. This training program will add an additional mode: active-resistance, with the affected arm/wrist actively moving against resistance.
Study: NCT03829969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Toripalimab
Description: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy
Study: NCT04688021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 4 mg/m2/day administered IV day -10 through -9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2 mg/kg/day administered IV day -8 through -6.
Study: NCT01655264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation exercises for weak upper extremity
Description: The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
Study: NCT04688021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1.8 g/m2/day administered IV day -5 through -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Me-CCNU
Description: 250mg/m2 once administered orally on day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Description: 1.5mg/kg/day administered IV day -5 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8mg/kg administered IV on day -1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: 2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: 15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
Study: NCT02147990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Rociletinib will be administered to patients orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Rociletinib will be administered to patients orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Rociletinib will be administered to patients orally
Study: NCT01391156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3%Minoxidil lotion
Description: 3% Minoxidil lotion apply two times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Minoxidil with 0.1% Finasteride lotion
Description: 3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
Study: NCT03635177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
Study: NCT01556243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole breast irradiation
Study: NCT02393664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol, bupivacaine
Description: Nonintubated technique for thoracoscopic surgery using propofol infusion, intercostal and vagal blocks with bupivacaine infiltrations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane, rocuronium
Description: Conventional intubated general anesthesia for thoracoscopic surgery using sevoflurane and rocuronium, and tracheal intubation with a double-lumen tube or a endobronchial blocker.
Study: NCT05750511

Intervention type: DIAGNOSTIC_TEST
Intervention: molecular tissue analysis
Study: NCT02685384

Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not

Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
Study: NCT00943293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 IV on day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
Study: NCT04549168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant 10 mg tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matched to lemborexant 10 mg tablet.
Study: NCT02530151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine with clonidine
Description: see arm description

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: see arm description
Study: NCT01571089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-inspired anxiety treatment
Description: In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
Study: NCT00803374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
Study: NCT03895476

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: palatal wound will be cover with collagen and sutures
Description: after harvesting the graft from the palate, a collagen sponge will be sutured to cover the harvested site
Study: NCT03812289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03895476

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: palatal wound covered with platelet rich fibrin
Description: after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
Study: NCT03812289

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT04274179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet
Description: Low carb (20g/day), high fat, moderate protein diet. Started as an outpatient in clinic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Absence epilepsy medications
Description: At neurologist's discretion. \*OF NOTE\< THIS ARM IS COMPLETED
Study: NCT00676650

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 37.5 mg/day, oral, administered on a continuous daily dosing regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: 5 mg BID, oral
Study: NCT02068885

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feeding study
Description: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeding study
Description: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeding study
Description: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
Study: NCT02437851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery to remove anal or perianal cancer (SISCCA)
Study: NCT03526445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (4 ng/kg/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT01374490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer
Description: Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
Study: NCT00865956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Nurse case manager assigned to participant
Study: NCT01266577

Intervention type: OTHER
Group type: OTHER
Intervention: NSR MAGNETOM 7T
Description: The 7 Tesla scanner is a magnet system used to acquire magnetic resonance imaging and spectroscopy

Intervention type: OTHER
Group type: OTHER
Intervention: 1Tx x 32Rx Head Coil
Description: Used to perform proton imaging and spectroscopy in the human heads.
Study: NCT00756639

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks.
Study: NCT02825316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low residue diet
Description: Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
Study: NCT00569660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 subcutaneous daily for 7 days (every 4 week cycle)
Study: NCT02132650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACC training
Description: Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SS training
Description: Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
Study: NCT00604916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized oral care protocol - electronic toothbrush
Description: a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mimic protocol
Description: a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
Study: NCT03506841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
Study: NCT00881231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)
Study: NCT03845491

Intervention type: DEVICE
Intervention: Mechanical Thrombectomy
Description: Treatment of LVO with mechanical thrombectomy

Intervention type: DEVICE
Intervention: Mechanical Thrombectomy
Description: Treatment of LVO with mechanical thrombectomy

Intervention type: DEVICE
Intervention: Mechanical Thrombectomy
Description: Treatment of LVO with mechanical thrombectomy
Study: NCT03943134

Intervention type: OTHER
Intervention: Minimally Processed Human Umbilical Cord Membrane
Description: Implantation of minimally processed human umbilical cord membrane at the time of surgery

Intervention type: OTHER
Intervention: Standard Surgical Procedures
Description: Standard surgical intervention for at least one targeted acute upper extremity trauma
Study: NCT03281096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine hydrochloride
Description: patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill manufactured to mmic Berberine hydrochloride 100mg tablet
Study: NCT04742608

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical charts are reviewed
Study: NCT02912767

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.
Study: NCT03895476

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: palatal wound covered with a collagen sponge and cyanoacrylate
Description: after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
Study: NCT03808558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.
Study: NCT03895476

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: palatal wound covered with a stent
Description: after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
Study: NCT00077285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT00756639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain X-ray
Description: On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
Study: NCT05902793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device: V.A.C. VERAFLO™ Dressing Kit
Description: Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator device: Negative pressure wound drainage material
Description: Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation.
Study: NCT06058806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physical Therapy
Description: Multimodal Physical Therapy program consisting of electrophysical agents, manual therapy interventions, and core stability exercises
Study: NCT00077285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT00025935

Intervention type: DRUG
Intervention: Lithium
Study: NCT03953898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT00077285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03953898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT01548326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: one 40 mg Atorvastatin tablet orally per day for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one Placebo tablet orally per day for 10 days
Study: NCT01985282

Intervention type: BEHAVIORAL
Intervention: Nutrition Status Questionnaires and Physicial Function Test
Description: Nutrition status questionnaires will be administered, Physical functional status will be tested
Study: NCT03953898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO